English

Greiner Bio-One announces a recommended offer of SEK 1.00 per share to the shareholders of Vigmed Holding AB

Report this content

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important notice” at the end of this announcement and in the tender offer document which will be published shortly before the beginning of the acceptance period for the Offer.

Greiner Bio-One GmbH (“GBO”) hereby announces a recommended public offer to the shareholders of Vigmed Holding AB (publ) (“Vigmed”) to tender all shares in Vigmed to GBO at a price of SEK 1.00 in cash per share (the “Offer”). The shares in Vigmed are listed on Nasdaq First North.

Summary

  • GBO offers SEK 1.00 in cash per Vigmed share. The total offer value for all outstanding shares in Vigmed amounts to approximately SEK 65.7 million.
  • Vigmed's Independent Bid Committee has unanimously recommended Vigmed's shareholders to accept the Offer. The Independent Bid Committee has obtained a fairness opinion from the independent expert Navigo Partners stating that the Offer is fair from a financial point of view to the shareholders of Vigmed.
  • Shareholders – including among others Bure Equity AB, Soliver Ltd., Per Knutsson, Cecilia Karlsson and Rikard Roos – representing in aggregate 29.37 per cent of the number of outstanding shares and votes in Vigmed, have subject to certain conditions irrevocably undertaken to accept the Offer.
  • The Offer is not subject to any financing condition. GBO has sufficient funds to complete the Offer.
  • An offer document regarding the Offer is expected to be made public on or about 5 March 2017. The acceptance period for the Offer is expected to begin on or about 6 March 2017 and expire on or about 27 March 2017.

"Through this acquisition, we are able to expand our product portfolio within Greiner Bio-One. With our strong brand and market position in hospitals we can support a broad uptake of Vigmed's opportunities, while we strengthen Vigmed's operational and financial position to enable a successful execution of its ambitions. This combination offers great future business potential for both parties", said Rainer Perneker, CEO of the Greiner Bio-One group.

"At Vigmed, we have focused on understanding the customer needs and turning these into product innovation. The opportunity to combine the synergetic and complementary competences and product portfolios of Vigmed and Greiner Bio-One, ensures a more efficient and competitive position. This will create a solid platform for major stakeholders – including customers, employees and contract manufacturers – that will provide a stronger long-term base for success for the Vigmed product portfolio. ", said Henrik Olsen, CEO of Vigmed. 

For additional information, please contact:

Georg Heftberger, Chief Financial Officer, Greiner Bio-One GmbH, tel. +43 664 8841 0683

Eric Tapper, Hallvarsson & Halvarsson, tel. +46 8 407 21 80

For information and documentation regarding the Offer, please visit: www.gbo-vigmed.se/en/

This press release was submitted for publication on 27 February 2017 at 07:45 a.m. CET.

Documents & Links